Who Paid My Doc
Qsymia
Drug Endocrinology
NDC 62541-202-30
General payments
$2,950,636
Research payments
$9,100,948
Through program year 2025, $2,950,636 in general payments and $9,100,948 in research payments were reported against Qsymia (Endocrinology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
12 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $144,528 | 1,260 |
| 2024 | General | $143,972 | 2,228 |
| 2023 | General | $635,454 | 2,015 |
| 2023 | Research | $3,424,695 | 229 |
| 2022 | General | $488,054 | 2,404 |
| 2022 | Research | $1,281,792 | 83 |
| 2021 | General | $511,616 | 3,037 |
| 2021 | Research | $822,451 | 101 |
| 2020 | General | $527,247 | 967 |
| 2020 | Research | $3,181,841 | 238 |
| 2019 | General | $499,766 | 2,311 |
| 2019 | Research | $390,169 | 37 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 47 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 39 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
14,222 general · 688 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.